Findings from the HELEN-006 trial suggest a potential shift in neoadjuvant treatment practices for patients with HER2-positive early breast cancer, specifically using nab-paclitaxel to reduce ...
In the US, there was a 7.6% increase in the price of cancer drugs at 5 years post-launch and an 18.1% increase at 10 years, after adjusting for inflation. Prices of cancer drugs increase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback